Theralase Technologies announced it demonstrated increased efficacy from their anti-cancer drug TLD-1633 compared to its lead anti-cancer drug TLD-1433.
Theralase Technologies (TSXV:TLT; OTCQX:TLTFF) announced it demonstrated increased efficacy from their anti-cancer drug TLD-1633 compared to its lead anti-cancer drug TLD-1433.
As quoted in the press release:
The latest PDC, known as TLD-1633, has recently been shown to be approximately 15% more effective than TLD-1433 in the destruction of a human Glioblastoma Multiforme (“GBM“) cell line (U87), a deadly form of brain cancer.
In preclinical research, TLD-1633 has also demonstrated a lower dark toxicity, supporting an even higher safety profile than TLD-1433.
Pavel Kaspler, Ph.D., a research scientist at Theralase, stated that, “Research on Theralase’s latest licensed anti-cancer drug, TLD-1633, is showing even stronger data preclinically than Theralase’s top performing anti-cancer drug TLD-1433. I look forward to expanding my research to assess the performance of TLD-1633 in various cancer lines, with and without the use of transferrin, as a transport system.”